Security key
47103J105
Janux Therapeutics, Inc. - Common Stock (JANX)
CUSIP: 47103J105
Q2 2023 13F Holders as of 30 Jun 2023
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 60,817,522
- Total 13F shares
- 30,508,831
- Share change
- -33,042
- Total reported value
- $362,117,070
- Put/Call ratio
- 8.3%
- Price per share
- $11.87
- Number of holders
- 54
- Value change
- -$408,523
- Number of buys
- 29
- Number of sells
- 19
Report period
Q2 2023
Institutions
54
Top holders
10
JANX full security history
Newer quarter: Q3 2023
Previous quarter: Q1 2023
Janux Therapeutics, Inc. SEC filings
Janux Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 47103J105
Recent filing periods:
Top shareholders of JANX - Janux Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
14%
|
8,670,644
|
$104,914,792 | — | 31 Mar 2023 | |
| FMR LLC |
13F
|
Company |
8.5%
|
5,140,644
|
$62,201,792 | — | 31 Mar 2023 | |
| EcoR1 Capital, LLC |
13F
|
Company |
6.3%
|
3,838,486
|
$46,445,681 | — | 31 Mar 2023 | |
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director |
4.7%
|
2,836,386
|
$34,320,271 | — | 31 Mar 2023 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3.1%
|
1,869,076
|
$22,611,527 | — | 31 Mar 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3%
|
1,853,026
|
$22,421,615 | — | 31 Mar 2023 | |
| Bregua Corp |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,749,250
|
$22,008,098 | — | 15 Jun 2021 | |
| BVF INC/IL |
13F
|
Company |
2.6%
|
1,585,677
|
$19,186,692 | — | 31 Mar 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.9%
|
1,134,645
|
$13,729,205 | — | 31 Mar 2023 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.5%
|
900,000
|
$10,890,000 | — | 31 Mar 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.3%
|
772,655
|
$9,349,125 | — | 31 Mar 2023 | |
| Samsara BioCapital, LLC |
13F
|
Company |
0.59%
|
360,414
|
$4,361,009 | — | 31 Mar 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.58%
|
354,585
|
$4,290,478 | — | 31 Mar 2023 | |
| STATE STREET CORP |
13F
|
Company |
0.49%
|
298,629
|
$3,613,411 | — | 31 Mar 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.23%
|
139,971
|
$1,693,650 | — | 31 Mar 2023 | |
| Woodline Partners LP |
13F
|
Company |
0.23%
|
137,300
|
$1,661,330 | — | 31 Mar 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.21%
|
129,631
|
$1,568,000 | — | 31 Mar 2023 | |
| Vident Investment Advisory, LLC |
13F
|
Company |
0.09%
|
55,483
|
$671,344 | — | 31 Mar 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.09%
|
53,091
|
$642,401 | — | 31 Mar 2023 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.08%
|
49,500
|
$574,000 | — | 31 Mar 2023 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.08%
|
45,903
|
$555,000 | — | 31 Mar 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.07%
|
45,392
|
$549,243 | — | 31 Mar 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.06%
|
34,103
|
$413,000 | — | 31 Mar 2023 | |
| MORGAN STANLEY |
13F
|
Company |
0.06%
|
33,504
|
$405,399 | — | 31 Mar 2023 | |
| Swiss National Bank |
13F
|
Company |
0.04%
|
27,000
|
$326,700 | — | 31 Mar 2023 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
26,849
|
$325,000 | — | 31 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.04%
|
23,737
|
$287,217 | — | 31 Mar 2023 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.03%
|
17,331
|
$209,705 | — | 31 Mar 2023 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.02%
|
13,248
|
$160,301 | — | 31 Mar 2023 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.02%
|
13,167
|
$159,321 | — | 31 Mar 2023 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.02%
|
12,728
|
$154,009 | — | 31 Mar 2023 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.02%
|
11,555
|
$139,816 | — | 31 Mar 2023 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.02%
|
10,614
|
$128,429 | — | 31 Mar 2023 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.02%
|
10,458
|
$126,542 | — | 31 Mar 2023 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
8,904
|
$107,738 | — | 31 Mar 2023 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
8,282
|
$100,212 | — | 31 Mar 2023 | |
| Legal & General Group Plc |
13F
|
Company |
0.01%
|
4,710
|
$56,991 | — | 31 Mar 2023 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,344
|
$40,000 | — | 31 Mar 2023 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
3,085
|
$37,328 | — | 31 Mar 2023 | |
| AMALGAMATED BANK |
13F
|
Company |
0%
|
1,784
|
$22,000 | — | 31 Mar 2023 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0%
|
1,532
|
$18,537 | — | 31 Mar 2023 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
1,014
|
$12,269 | — | 31 Mar 2023 | |
| METROPOLITAN LIFE INSURANCE CO/NY |
13F
|
Company |
0%
|
1,004
|
$12,148 | — | 31 Mar 2023 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
960
|
$12,000 | — | 31 Mar 2023 | |
| UBS Group AG |
13F
|
Company |
0%
|
841
|
$10,176 | — | 31 Mar 2023 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
559
|
$6,764 | — | 31 Mar 2023 | |
| TUCKER ASSET MANAGEMENT LLC |
13F
|
Company |
0%
|
250
|
$3,025 | — | 31 Mar 2023 | |
| Crewe Advisors LLC |
13F
|
Company |
0%
|
115
|
$1,392 | — | 31 Mar 2023 | |
| US BANCORP \DE\ |
13F
|
Company |
0%
|
90
|
$1,089 | — | 31 Mar 2023 | |
| Shahram Salek-Ardakani |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
114,250
|
— | — | 03 Jan 2022 |
Institutional Holders of Janux Therapeutics, Inc. - Common Stock (JANX) as of Q2 2023
As of 30 Jun 2023,
Janux Therapeutics, Inc. - Common Stock (JANX) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,508,831 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., FMR LLC, BVF INC/IL, ORBIMED ADVISORS LLC, CITADEL ADVISORS LLC, JANUS HENDERSON GROUP PLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., VANGUARD GROUP INC, and EcoR1 Capital, LLC.
This page lists
54
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
48
Q2 2023 holders
54
Holder diff
6
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 Value $ | Q2 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.